Progressive Relaxation and Psychoeducation in Patients With Hematological Malignancies

May 14, 2026 updated by: Tuba KORKMAZ ASLAN, Necmettin Erbakan University

The Effect of Progressive Relaxation and Psychoeducation on Perceived Stress and Hope in Patients With Hematologic Malignancies: A Non-Randomized Study

This study will be conducted to determine the effect of progressive relaxation and psychoeducation on perceived stress and hope in patients with hematological malignancies

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Being healthy requires being in a state of complete physical and mental well-being. Therefore, mental and physical well-being must be maintained together. While each individual already has different stressors, the fact that hematological malignancies are chronic and immune-mediated diseases increases the stress factors perceived by individuals, and the difficulty and uncertainty of the process reduces their level of hope. This triggers the use of ineffective coping methods. Patients with high perceived stress levels and declining hope levels are unable to adequately manage the disease process. Consequently, mortality and morbidity rates increase. This experimentally planned study will be conducted between February 2026 and November 2026 at the Adult Inpatient Hematology Clinic of Gazi University Faculty of Medicine Hospital. The study will involve 75 individuals hospitalized at the clinic who meet the inclusion criteria. It is a non-randomized study with 2 intervention groups and 1 control group. Intervention group A (progressive relaxation group, n=25), intervention group B (psychoeducation, n=25), and control group (routine care, n=25). Patients in intervention group A will undergo a 3-week, 6-session progressive relaxation exercise program, conducted individually and face-to-face. Intervention Group B will receive a 3-week, 6-session, individual, face-to-face psychoeducation program. The control group will receive 3 weeks of routine nursing care identical to that provided to the other groups. In this study, which will include pre- and post-tests, data will be collected face-to-face using the perceived stress level scale and the Herth hope index scale. The primary objective of this study is to examine the effects of progressive relaxation and psychoeducation interventions on perceived stress and hope levels in patients with hematological malignancies.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
75

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey (Türkiye)
    • Seydi̇şehi̇r
      • Konya, Seydi̇şehi̇r, Turkey (Türkiye), 42000
        • Seydişehir Kamil Akkanat Sağlik Bilimleri Fakültesi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. 18 years of age or older
  2. Diagnosis of hematologic malignancy
  3. Ability to read and write
  4. Volunteer to participate in the study

Exclusion Criteria:

  1. Dementia and/or organic mental disorder
  2. Sensory loss related to vision and hearing
  3. Communication barrier
  4. Physical disability
  5. Respiratory distress
  6. Bone marrow transplant procedure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Progressive relaxation

Progressive relaxation; n=25: After the pre-test, 6 sessions (2 sessions per week) were planned for 3 weeks for individuals in this group. Each session will be conducted individually with patients, face-to-face, and will last 40-45 minutes. The post-test was administered after 3 weeks.

PROGRESSIVE RELAXATION SESSION TITLES:

  1. SESSION: Introduction, Establishing Trust and the Concept of Relaxation
  2. SESSION: Coping with a Cancer Diagnosis & Introduction to the Progressive Relaxation Technique
  3. SESSION: Progressive Muscle Relaxation Application - Upper Body3
  4. SESSION: Progressive Muscle Relaxation - Lower Body
  5. SESSION: Whole Body Relaxation - Reinforcing the Application
  6. SESSION: Integrating Progressive Relaxation into Daily Life & Closing
Behavioral: Muscle Relaxation

Progressive relaxation is a relaxation technique based on tensing and relaxing muscles in sequence. The goal is to achieve physical and mental relaxation by feeling the difference between tension and relaxation. It is frequently used for stress, anxiety, sleep problems, and psychosomatic disorders. When practiced regularly, it increases a person's ability to relax and contributes to their overall well-being.

  • Teaching progressive relaxation exercises to individuals diagnosed with cancer and supporting psychological well-being by reducing stress levels and increasing hope levels through these exercises (emotional gain)
  • Reducing muscle tension and providing physical relaxation (psychomotor gain)
  • To reduce stress and anxiety (emotional gain)
  • To increase body awareness (emotional gain)
  • To teach mental and physical relaxation (psychomotor gain)
  • To provide emotional relief (emotional gain)
  • To develop self-relaxation skills (psychomotor gain)
Active Comparator: psychoeducation

psychoeducation; n=25: After the pre-test, 6 sessions (2 sessions per week) were planned for 3 weeks for the individuals in this group. Each session will be conducted individually with patients, face-to-face, and will last 40-45 minutes. A post-test was administered after 3 weeks. Four expert opinions were obtained regarding the content.

PSYCHOEDUCATION SESSION TITLES:

1. SESSION: INTRODUCTION AND PROGRAM OVERVIEW 2nd SESSION: UNDERSTANDING THE DISEASE - EMPOWERING THROUGH KNOWLEDGE 3rd SESSION: IDENTIFYING PERCEIVED STRESS AND ITS EFFECTS 4. SESSION: COPING WITH STRESS AND INTRODUCTION TO HOPE 5. SESSION: UNDERSTANDING AND STRENGTHENING HOPE 6. SESSION: INTERNALIZING WHAT HAS BEEN LEARNED, MAINTAINING AND EVALUATING
Behavioral: psychoeducation or Atomoxetine or stimulants according to ADHD severity

Psychoeducation is a structured educational process that provides individuals with information about mental illnesses, ways to cope with stress, and healthy living skills. The goal is to help the person understand their illness and symptoms, learn coping methods, and increase their compliance with treatment. It has both an informative and a supportive aspect.

INTERVENTION B (PSYCHOEDUCATION) GROUP APPLICATION:

  • A total of 6 sessions will be held with patients in intervention group B, twice a week for 3 weeks.
  • Each session will last an average of 45 minutes.
  • The 'Perceived Stress Level' scale and the 'Herth Hope Index' scale will be administered after the first session.
  • The 'Perceived Stress Level' scale and the 'Herth Hope Index' scale will be administered after the final session.
No Intervention: routine nursing care
routine nursig care; n=25 No intervention was performed after the pre-test; routine nursing care was administered. The post-test was administered after 3 weeks.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Herth hope index level scale
Time Frame: 9 months
Herth Hope Index: Developed by Kaye Herth (1992), its validity and reliability in Turkish were studied by Aslan and colleagues (2007). The scale consists of a total of 12 items: "Future" (questions 1, 2, 6, 11), "Positive readiness and expectation" (questions 4, 7, 10, 12), and "Connections with oneself and others" (questions 3, 5, 8, 9).
9 months
perceived stress level scales
Time Frame: 9 months
PERCEIVED STRESS SCALE: The adaptation of the perceived stress scale developed by Cohen, Kamarck, and Mermelsten (1983) into Turkish was carried out by Eskin et al. (2013). The perceived stress scale, consisting of a total of 14 items, aims to measure how stressful individuals perceive their life situations to be..
9 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Necmettin Erbakan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 30, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 30, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 11, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 18, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 26, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 15, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 14, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NEÜ-SBF-TKA-02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings